GIST culture morphology and pathology plus osteosarcoma tissue and PDO markers show how two projects guide model QC and follow-on assays.
STUDY EVIDENCE
Two mesenchymal-tumor studies show how culture morphology, source pathology and model markers can be combined for identity, quality assessment and downstream assay design.
Bright-field culture morphology, source-tissue H&E and culture H&E compare spindle and mixed spindle/epithelioid patterns within a case-specific pathology reference.
Defines model-QC priorities and downstream identity assays
H&E, Vimentin, Ki67, SOX9 and TP53 panels compare model identity, proliferation and lineage-associated phenotypes.
Guides program-relevant marker and functional endpoint selectionINTERPRETATION
Helps select candidate- or mechanism-focused studies suited to the culture system.
Culture phenotype is interpreted with tissue source, pathology and program-specific QC, then validated through functional endpoints and independent batches.
Start with source context and appropriate controls, then add dose, time and functional endpoints with independent-batch validation.
Related models and services
PROJECT DISCUSSION
Tell us which model, assay or finding you want to extend. Our scientists will adapt the approach to your candidate, samples and decision point.
